Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
On the heels of the landmark [url="]OPTIMA trial[/url] readout presented at the ASCO Annual Meeting, Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostic
Open original source